WO2021103581A1 - 具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物 - Google Patents
具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物 Download PDFInfo
- Publication number
- WO2021103581A1 WO2021103581A1 PCT/CN2020/102452 CN2020102452W WO2021103581A1 WO 2021103581 A1 WO2021103581 A1 WO 2021103581A1 CN 2020102452 W CN2020102452 W CN 2020102452W WO 2021103581 A1 WO2021103581 A1 WO 2021103581A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- composition
- extract
- external
- sap
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
Definitions
- the present invention relates to an external skin composition with the effect of promoting wound healing and/or scar repair, which comprises (A) concentrated birch tree sap, and (B) Sanguis frondosa root extract, coptis root extract, and comfrey extract One or more of extracts, allantoin, salvia extract, astragalus extract, pearl powder and asiaticoside, wherein the concentration of the concentrated birch sap is about 1.2-6 times, preferably about 1.5 -5 times, more preferably about 1.5-3 times.
- Scars are caused by physical, biological, chemical and other factors. Especially after burns, scalds, and trauma, the lesions of human skin and soft tissues exceed the original skin damage range, and the continuous performance is higher than the surface of the skin, with hard texture and congestion. Shaped, strip-shaped or flaky mass-like tissue. The years of scar hyperplasia almost made the patient uncomfortable. The subsequent period of atrophy makes the patient completely unrecognizable and dysfunctional, which causes the patient's great physical and mental dual obstacles.
- the main improvement or treatment methods for scars include gene therapy, intra-scar drug injection, oral anti-scarring drugs, cryotherapy, pressure therapy, laser treatment, silicone gel film products, radiation therapy, etc.
- the therapeutic effects of various treatment methods are also not exactly. However, they all have the disadvantages of slow response, long cycle, difficult to cure, and large toxic and side effects.
- Wound healing is a complex dynamic process. The cell structure and the tissue layer of the damaged tissue are restored to a normal state as much as possible. It is a complex organism that is highly coordinated and regulated by a variety of cells, extracellular matrix and cytokines. Learning process. Wound healing can be roughly divided into 4 gradual and overlapping processes, namely, hemostasis, inflammation, proliferation and remodeling. Hemostasis and inflammation are two phases with different characteristics in the inflammatory phase; the proliferative phase includes epithelialization, angiogenesis, and collagen deposition; scarring may occur during the contraction of tissue wounds in the mature phase. Reduce inflammation, promote fibroblast proliferation and angiogenesis, which will help the rapid healing of wounds. The pathological basis of hypertrophic scars is the excessive proliferation of fibroblast-based cellular components and the excessive deposition of collagen-based extracellular matrix. Controlling the inflammatory response and reducing the excessive deposition of extracellular collagen can reduce and Repair scars.
- Birch sap is the sap from the birch family plant, rich in active ingredients such as polysaccharides, amino acids, vitamins, biotin, cytokinins, minerals and trace elements needed by the human body. There are records of using birch tree sap to treat burns and scalds in Europe. Naturally sourced birch sap has great potential in promoting wound healing and repairing scars.
- FIG. 1 is a graph showing the cell migration rate obtained in Example 2.
- FIG. 2 is a graph showing the degree of wound healing obtained in Example 3.
- FIG. 1 is a graph showing the cell migration rate obtained in Example 2.
- the present invention relates to the use of a concentrated birch sap in a skin external composition with the effect of promoting wound healing and/or scar repair, wherein the concentration of the concentrated birch sap is about 1.2-6 times , Preferably about 1.5-5 times, more preferably about 1.5-3 times.
- the present invention relates to a skin external composition with the effect of promoting wound healing and/or scar repair, which comprises (A) concentrated birch tree sap, wherein the concentration multiple of the concentrated birch tree sap is about 1.2 -6 times, preferably about 1.5-5 times, more preferably about 1.5-3 times.
- the birch sap involved in the present invention is obtained from the genus Betula, Betula alba, Betula pubescens, Betula pendula and Asian white birch (Betula platyphylla). Varieties.
- the birch sap is a colorless, transparent, no-sediment-free, and nutrient-rich sap that is collected by artificially drilling holes in the base of the trunk of the birch tree between thawing and early spring.
- the birch sap is commercially available and used as it is, for example, it can be purchased from Daxinganling Chaoyue Wild Berry Development Co., Ltd.
- the concentrated birch sap in the present invention is obtained by concentrating the above-mentioned commercial products. Concentration methods are known in the art, such as heating concentration, low-temperature vacuum concentration, membrane concentration and the like. In the present invention, the concentration is preferably carried out by a low-temperature freeze concentration or membrane concentration process. For example, the commercially available birch juice stock solution is fed into a low-temperature drying equipment, the temperature is lowered to about -40°C to -70°C, and the vacuum is reduced to about 0.1-30 Pa The low-temperature vacuum concentration is performed to obtain concentrated birch sap with different concentration multiples.
- the content of the (A) concentrated birch tree juice in the skin external composition is about 10-98% by weight, preferably about 20-98%, more preferably about 30-97%, based on the skin external composition The total weight.
- the present inventors unexpectedly discovered that the use of concentrated birch sap or Sanyu root extract, Coptis root extract, comfrey extract, allantoin, salvia extract, astragalus extract, pearl Compared with powder and asiaticoside, the concentrated birch sap is compared with elm root extract, berberine root extract, comfrey extract, allantoin, salvia extract, astragalus extract, pearl powder and asiaticoside
- the combination of one or more of them has a significantly better effect of promoting wound healing and/or repairing scars, which is significantly higher than the functional superimposition effect of the two, which is shown to better promote the migration of fibroblasts and promote skin defect model rats Wound healing rate, while inhibiting inflammation-related TNF- ⁇ and IL-6 protein content, reducing rabbit scar hyperplasia index and scar tissue collagen deposition and the degree of scarring in human body, which shows that the concentrated birch tree sap and the above substances occur between A synergistic effect.
- the present invention relates to (A) concentrated birch sap and (B) Sanguisorba paniculata root extract, coptis root extract, comfrey extract, allantoin, salvia miltiorrhiza extract, astragalus extract, pearl Use of a combination of one or more of asiaticoside powder and asiaticoside in a skin external composition having the effect of promoting wound healing and/or scar repair, wherein the concentration multiple of the concentrated birch sap is 1.2-6 Times, preferably 1.5-5 times, more preferably 1.5-3 times.
- the present invention relates to a skin external composition with the effect of promoting wound healing and/or scar repair, which comprises (A) concentrated birch tree sap, wherein the concentration multiple of the concentrated birch tree sap is about 1.2 -6 times, preferably about 1.5-5 times, more preferably about 1.5-3 times, and (B) Sanguisorba paniculata root extract, Coptis root extract, Lithospermum extract, Allantoin, Salvia miltiorrhiza extract, Astragalus extract , Pearl powder and one or more of asiaticoside.
- the component (B) Sanguis frondosa root extract, Coptis root extract, comfrey extract, allantoin, salvia miltiorrhiza extract, astragalus extract, pearl powder and asiaticoside are known in the art, and they All are commercially available and used in the present invention as they are.
- the total content of the component (B) in the external skin composition is about 0.0005-30%, preferably about 0.001-10%, more preferably about 0.1-5%, most preferably about 0.5-3%, based on The total weight of the external skin composition.
- the external skin composition includes a pharmaceutical composition and a skin care cosmetic composition, wherein the pharmaceutical composition shows a significant wound healing and scar repairing effect, and the skin care cosmetic composition shows a significant scar repairing effect.
- the external skin composition does not contain any added water, but does not exclude the moisture inherently contained in each component.
- the external skin composition does not contain chelating agents such as EDTA salt, sodium polyphosphate, sodium metaphosphate, and gluconic acid.
- chelating agents such as EDTA salt, sodium polyphosphate, sodium metaphosphate, and gluconic acid.
- the external skin composition may optionally include component (C) used in wound healing and/or scar repair compositions.
- component (C) include, but are not limited to, vehicles, active ingredients, excipients, and the like. These ingredients are known in the art, and those skilled in the art can select the type and amount of component (C) according to their needs.
- the content of component (C) is usually about 0-70%, based on the external use of the skin. The total weight of the composition.
- the vehicle includes, for example, a diluent, a dispersant, or a carrier, and examples thereof include, but are not limited to, ethanol, dipropylene glycol, butylene glycol, and the like.
- the content of the vehicle in the skin topical composition is known in the art, for example, it usually accounts for about 0.5-20% of the total weight of component (C).
- the active ingredients include antibacterial agents, anti-inflammatory agents, astringents, moisturizers and the like.
- the antibacterial agents include, but are not limited to, ursolic acid, oldenlandia diffusa flavonoids, honeysuckle flower extract, tea tree essential oil, chitin, cinnamon twig extract, coral ginger volatile oil, clove extract, mushroom extract, aloe extract, One or more of mugwort leaf extract, 1-pentadecanol and its derivatives, cedarene, caryophyllene, and phyllene.
- the content of the antibacterial agent in the skin external composition is known in the art, for example, it usually accounts for about 0.01-30% of the total weight of the component (C).
- the anti-inflammatory agents include, but are not limited to, safflower yellow, dipotassium glycyrrhizinate, cattail pollen extract, arrowroot extract, cucumber extract, garlic extract, burdock extract, resveratrol, Sophora flavescens extract, One or more of Magnolia Bark Extract, etc.
- the content of the anti-inflammatory agent in the skin external composition is known in the art, for example, it usually accounts for about 0.01-50% of the total weight of the component (C).
- the astringent includes, but is not limited to, green tea polyphenols, witch hazel extract, vitamin A, menthol lactate, seaweed extract, Indigo Naturalis, sulfur, rehmannia, angelica, lactic acid, tartaric acid, succinic acid, citric acid, etc.
- the content of the astringent in the skin external composition is known in the art, for example, it usually accounts for about 0.01-30% of the total weight of the component (C).
- moisturizer examples include, but are not limited to, glycerin, diglycerin, butylene glycol, propylene glycol, 1,3-propanediol, dipropylene glycol, 1,2-pentanediol, polyethylene glycol-8, polyethylene glycol Alcohol-32, methylglucitol-10, methylglucitol-20, PEG/PPG-17/6 copolymer, glycerol-7, glycerol-26, glycerol glucoside, PPG-10 methyl glucose ether, PPG-20 methyl glucose ether, PEG/PPG/polybutylene glycol-8/5/3 glycerin, sucrose, trehalose, rhamnose, mannose, raffinose, Betaine, erythritol, xylitol, urea, polyglycerol-5 lactate, sodium hyaluronate, hydrolyzed sodium hyaluronate, acetylated sodium
- auxiliary materials include, for example, surfactants, emulsifiers, thickeners, preservatives, perfumes and the like.
- surfactant examples include, but are not limited to, cocamidopropyl betaine, sodium laureth sulfate, PEG-150 distearate, ethylene glycol distearate, lauryl polyoxyethylene Ammonium ether sulfate, sodium lauryl ether sulfate, palmamide propyl betaine, cocamide diethanolamine, lauryl ether sulfate, ammonium lauryl sulfate (K12A), fatty alcohol polyvinyl ether sulfate Sodium (AES), fatty alcohol polyvinyl ether ammonium sulfate (AESA), ammonium laureth sulfate, ammonium lauryl sulfate, sodium lauryl sulfate, ammonium lauryl polyether sulfate, ammonium lauryl sulfate, coconut Oleyl monoethanolamide, N-fatty acyl amino acid salt, lauramide propyl betaine, sodium cocoampho
- emulsifier examples include, but are not limited to, cetearyl oleate, sorbitan oleate, polysorbate-60, polysorbate-80, methylglucose sesquistearic acid Ester, PEG-20 methyl glucose sesquistearate, PEG-40 hydrogenated castor oil, PPG-26-butanol-26, PEG-4 polyglycerol-2 stearate, PEG-60 hydrogenated Castor oil, steareth-2, steareth-21, PPG-13-decyltetradeceth-24, cetearyl glucoside, PEG-100 stearate, glycerin Stearate, Glyceryl Stearate SE, Coco Glucoside, Ceteareth-25, PEG-40 Stearate, Polyglyceryl-3 Methyl Glucose Distearate, Glyceryl stearate citrate, polyglyceryl-10 stearate, polyglyceryl-10 myristate, polyglyce
- the thickener examples include, but are not limited to, carbomers, acrylic acid (ester) and its derivatives, xanthan gum, gum arabic, polyethylene glycol-14M, polyethylene glycol-90M, succinyl poly One or more of high molecular polymers such as sugar, hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose.
- the content of the thickener in the external skin composition is known in the art, for example, it usually accounts for about 0.1-30% of the total weight of the component (C).
- preservatives examples include, but are not limited to, methyl paraben, ethyl paraben, propyl paraben, phenoxyethanol, benzyl alcohol, phenethyl alcohol, bis(hydroxymethyl)imidazolidinyl urea, potassium sorbate, One or more of sodium benzoate, chlorphenesin, sodium dehydroacetate, etc.
- the content of the preservative in the skin external composition is known in the art, for example, it usually accounts for about 0.01-30% of the total weight of the component (C).
- the external skin composition of the present invention can be prepared by any suitable method known in the art.
- it can be prepared by dissolving tanks, emulsifying pots, dispersers, and delivery pumps commonly used in the cosmetics field.
- dissolving tanks emulsifying pots, dispersers, and delivery pumps commonly used in the cosmetics field.
- When preparing put the water-soluble substance into the water-phase dissolving kettle, and the oil-soluble substance into the oil-phase dissolving kettle, and heat the temperature of the two kettles to about 80°C.
- the raw materials that are easy to agglomerate they can be firstly mixed with a disperser. Pre-dispersed. After the dissolution is completed, the oil phase and the water phase are transported to the emulsifying pot for homogenization and emulsification for about 5-15 minutes.
- the temperature of the material body is lowered to normal temperature, optional flavors, preservatives, etc. are added, and the pH of the product is adjusted as needed.
- the products can be filled and shipped only after the relevant test indicators are qualified.
- the above preparation methods can be deleted or adjusted according to the requirements of the dosage form.
- compositions or skin care cosmetic compositions in various dosage forms such as liquids, emulsions, creams, creams or gels can be prepared as needed, wherein the skin care cosmetic compositions can be lotions, sprays, emulsions, essence water or essence milk, Various forms such as frost.
- the cells used in this test are human-derived fibroblasts, obtained by Guangdong Boxi Biotechnology Co., Ltd. through primary and passage.
- Cell inoculation Inoculate cells into a 96-well plate at a seeding density of 1E4 cells/well, and incubate overnight in an incubator (37°C, 5% CO 2 , 95% RH).
- the experiment set up blank control group, positive control group and sample group.
- the pre-prepared culture solution with the sample to be tested is administered in groups, and the dosage per well is 200 ⁇ L, and each group has 3 multiple wells.
- the positive control group 200 ⁇ L of culture medium containing dermatan sulfate (5 ⁇ M) was added to each well; in the sample group, 200 ⁇ L of culture medium containing the corresponding concentration of the test substance was added to each well; the zero hole was adjusted without cell inoculation, and only 200 ⁇ L of cell culture medium was added.
- the 96-well plate was placed in an incubator (37°C, 5% CO 2 , 95% RH) for culture.
- Birch sap solution (80% birch sap stock solution + 20% water) 2% ⁇ 1% Birch sap 4% ⁇ 2% 1.2 times concentrated birch sap 14% ⁇ 1%* 2 times concentrated birch sap 21% ⁇ 3%** 3 times concentrated birch sap 16% ⁇ 3%** 5 times concentrated birch sap 12% ⁇ 2%*
- the cells used in this test are human-derived fibroblasts, obtained by Guangdong Boxi Biotechnology Co., Ltd. through primary and passage.
- the fresh birch sap stock solution purchased from Daxinganling Chaoyue Wild Berry Development Co., Ltd. is fed into the low-temperature drying equipment, cooled to -65°C, vacuumed to 0.1Pa, and concentrated to 3 times.
- the loading amount of a single raw material is a whole raw material; the compound raw material is half a birch sap raw material plus half a 0.1% other active raw material.
- the tested samples include: 3 times concentrated birch sap, Sanyu root extract, Coptis root extract, 3 times concentrated birch sap + Sanguinea root extract, and 3 times concentrated birch sap + Coptis root extract .
- the fresh white birch sap stock solution purchased from Daxinganling Chaoyue Wild Berry Development Co., Ltd. is fed into the low-temperature drying equipment, cooled to -65°C, vacuumed to 0.1Pa, and concentrated to 1.5 times.
- the loading amount of a single raw material is a whole raw material; the compound raw material is half a birch sap raw material plus half a 0.1% other active raw material.
- the tested samples include: 1.5 times concentrated birch sap, comfrey extract, allantoin, 1.5 times concentrated birch sap + comfrey root extract, and 1.5 times concentrated birch sap + allantoin.
- the SD rats were randomly divided into a blank control group and an experimental group treated with different samples according to 6 in each group.
- the rats were given isoflurane inhalation anesthesia, and the experiment was performed when the symptoms of general weakness, muscle relaxation, corneal reflex and pain response disappeared;
- control group used PBS or Ringer's solution and covered the wound with a 3M transparent film; the sample group was sprayed with test samples of different concentrations.
- the frequency of wound medication is once a day.
- Digital thickness gauge multi-function microplate reader, high-throughput tissue grinder, slicer, tissue dehydrator, tissue embedding machine, microscope.
- the fresh white birch sap stock solution purchased from Daxinganling Chaoyue Wild Berry Development Co., Ltd. is fed into the low-temperature drying equipment, cooled to -65°C, vacuumed to 0.1Pa, and concentrated to 1.5 times.
- the loading amount of a single raw material is a whole raw material; the compound raw material is half a birch sap raw material plus half a 0.1% other active raw material.
- the tested samples include: 1.5 times concentrated birch sap, salvia miltiorrhiza extract, astragalus extract, 1.5 times concentrated birch sap + salvia extract, and 1.5 times concentrated birch sap + astragalus extract.
- pentobarbital sodium 1.0mL/kg (30mg/kg) was used for ear vein anesthesia, and the ventral skin of the rabbit ears was disinfected with iodophor and ethanol. Avoid visible blood vessels along the long axis, use a corneal ring to gently drill a 1cm ⁇ 1cm wound with an interval of more than 1cm. Remove the entire layer of rabbit ears and use a spatula to completely scrape the perichondrium. Sterile cotton balls are used to stop bleeding. In 4 locations, the postoperative wounds were exposed. Penicillin was injected intramuscularly for 2 consecutive days after the operation, with a dose of 40,000 units/kg. The wounds were fed normally until the wounds healed by themselves.
- Model animals were divided into groups, 6 animals in each group: the model group was raised normally without treatment; the treatment group included the model group (PBS group) and different sample treatment groups.
- Local smear administration once a day, smear 0.1mL on each scar.
- Scar hyperplasia index the vertical distance from the highest point of the scar to the surface of the ear cartilage/the thickness of the surrounding normal skin.
- tissue homogenate was prepared routinely, and the content of hydroxyproline was measured with a kit to investigate the degree of collagen deposition and fibrosis.
- the tissue homogenate was prepared by the same method, and the content of hydroxyproline was determined as a normal control group.
- Group Scar hyperplasia index HPr content ( ⁇ g/mg) Model group 3.06 ⁇ 0.19 5.88 ⁇ 0.79 1.5 times concentrated birch sap 2.53 ⁇ 0.16* 4.21 ⁇ 0.53* Salvia miltiorrhiza extract 2.98 ⁇ 0.09 4.36 ⁇ 0.49* Astragalus extract 2.77 ⁇ 0.12* 4.65 ⁇ 0.61* 1.5 times concentrated birch sap + salvia miltiorrhiza extract 1.55 ⁇ 0.14** 3.35 ⁇ 0.55** 1.5 times concentrated birch juice + astragalus extract 1.51 ⁇ 0.16** 3.84 ⁇ 0.37**
- Scar scoring is based on the Vancouver Scar Scale (VSS), which is comprehensively evaluated from four aspects: color, thickness, vascular distribution and softness. The total score is 15 points, the higher the score, the more severe the scar.
- the SPSS statistical software was used for statistical analysis. The measurement data was expressed as x ⁇ s. The paired t test was used for comparison within groups before and after treatment, and the group t test was used for comparison between groups. The ⁇ 2 test was used to compare the enumeration data between groups. P ⁇ 0.05 was considered statistically different.
- Example 6 Scar ointment for external use on the skin
- the preparation method of the above-mentioned topical scar ointment for skin is as follows:
- step (3) The solution obtained in step (2) is placed in the refrigerator to stand for 90 minutes, filtered with suction, and the filtrate is poured into a petri dish, covered with a perforated plastic wrap, and placed in a -80°C refrigerator for 24 hours Then take it out and put it in a vacuum freeze dryer to dry. When the mixture becomes a white fluffy mass, take it out for later use;
- step (3) Take another 75g of glycerol, 12g of triethanolamine, 7g of Tween-80, 2g of methyl paraben, 2g of ethyl paraben, and 12g of borneol.
- the formula of the skin care repair lotion is shown in the following table:
- the preparation method of the above skin care repair emulsion is as follows:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
因此,本发明人通过研究桦树汁在促进伤口愈合和/或疤痕修复中的功效完成了本发明。
附图说明
图1是显示实施例2中获得的细胞迁移率的图。
图2是显示实施例3中获得的创面愈合程度的图。
样品 | 成纤维细胞增殖率 |
桦树汁溶液(80%桦树汁原液+20%水) | 2%±1% |
桦树汁原液 | 4%±2% |
1.2倍浓缩的桦树汁 | 14%±1%* |
2倍浓缩的桦树汁 | 21%±3%** |
3倍浓缩的桦树汁 | 16%±3%** |
5倍浓缩的桦树汁 | 12%±2%* |
样品 | TNF-α | IL-6 |
正常组 | 1839±32 | 3567±29 |
模型组 | 2103±45 | 6654±43 |
1.5倍浓缩的桦树汁 | 1987±16* | 5054±44* |
紫草提取物 | 2043±22 | 5275±28* |
尿囊素 | 2011±31 | 5702±41 |
1.5倍浓缩的桦树汁+紫草提取物 | 1941±18* | 3987±38** |
1.5倍浓缩的桦树汁+尿囊素 | 1898±27** | 4442±22** |
组别 | 瘢痕增生指数 | HPr含量(μg/mg) |
模型组 | 3.06±0.19 | 5.88±0.79 |
1.5倍浓缩桦树汁 | 2.53±0.16* | 4.21±0.53* |
丹参提取物 | 2.98±0.09 | 4.36±0.49* |
黄芪提取物 | 2.77±0.12* | 4.65±0.61* |
1.5倍浓缩桦树汁+丹参提取物 | 1.55±0.14** | 3.35±0.55** |
1.5倍浓缩的桦树汁+黄芪提取物 | 1.51±0.16** | 3.84±0.37** |
编号 | 原料 | 重量g |
1 | 2倍浓缩桦树汁 | 300 |
2 | 丹参提取物 | 15 |
3 | 羟丙基-β-环糊精 | 125 |
4 | 硬脂酸 | 160 |
5 | 单硬脂酸甘油酯 | 100 |
6 | 十六醇 | 35 |
7 | 十八醇 | 35 |
8 | 白凡士林 | 80 |
9 | 羊毛脂 | 40 |
10 | 甘油 | 75 |
11 | 三乙醇胺 | 12 |
12 | 吐温-80 | 7 |
13 | 尼泊金甲酯 | 2 |
14 | 尼泊金乙酯 | 2 |
15 | 冰片 | 12 |
Claims (12)
- 一种浓缩的桦树汁在具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物中的用途,其中所述浓缩的桦树汁的浓缩倍数为1.2-6倍,优选1.5-5倍,更优选1.5-3倍。
- (A)浓缩的桦树汁与(B)地榆根提取物、黄连根提取物、紫草提取物、尿囊素、丹参提取物、黄芪提取物、珍珠粉和积雪草苷中的一种或多种的组合在具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物中的用途,其中所述浓缩的桦树汁的浓缩倍数为1.2-6倍,优选1.5-5倍,更优选1.5-3倍。
- 权利要求1或2所述的用途,其中所述组分(A)在所述皮肤外用组合物中的含量为10-98%重量、优选20-98%,更优选30-97%,基于所述皮肤外用组合物的总重量。
- 权利要求2-3任一项所述的用途,其中所述组分(B)在所述皮肤外用组合物中的总含量为0.0005-30%,优选0.001-10%,更优选0.1-5%,最优选0.5-3%,基于所述皮肤外用组合物的总重量。
- 权利要求1-4任一项所述的用途,其中所述皮肤外用组合物包括药物组合物和护肤化妆品组合物。
- 权利要求1-5任一项所述的用途,其中所述皮肤外用组合物不包含任何外加的水,但不排除各组分中固有地包含的水分。
- 一种具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物,其包含(A)浓缩的桦树汁,其中所述浓缩的桦树汁的浓缩倍数为1.2-6倍,优选1.5-5倍,更优选1.5-3倍。
- 权利要求7所述的皮肤外用组合物,其进一步包含(B)地榆根提取物、黄连根提取物、紫草提取物、尿囊素、丹参提取物、黄芪提取物、珍珠粉和积雪草苷中的一种或多种。
- 权利要求8所述的皮肤外用组合物,其中所述组分(B)在所述皮肤外用组合物中的总含量为0.0005-30%,优选0.001-10%,更优选0.1-5%,最优选0.5-3%,基于所述皮肤外用组合物的总重量。
- 权利要求7-9任一项所述的皮肤外用组合物,其中所述组分(A)浓缩的桦树汁在所述皮肤外用组合物中的含量为10-98%重量、优选20-98%,更优选30-97%,基于所述皮肤外用组合物的总重量。
- 权利要求7-10任一项所述的皮肤外用组合物,其中所述皮肤外用组合物包括药物组合物和护肤化妆品组合物。
- 权利要求7-11任一项所述的皮肤外用组合物,其不包含任何外加的水,但不排除各组分中固有地包含的水分。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022516746A JP2022549102A (ja) | 2019-11-28 | 2020-07-16 | 創傷治癒および/または瘢痕修復の促進の有効性を有する皮膚局所用組成物 |
KR1020227007759A KR20220051191A (ko) | 2019-11-28 | 2020-07-16 | 상처 치유 및/또는 흉터 복구를 촉진하는 효능을 가진 피부 국소용 조성물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911189594.4 | 2019-11-28 | ||
CN201911189594.4A CN110876760B (zh) | 2019-11-28 | 2019-11-28 | 具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021103581A1 true WO2021103581A1 (zh) | 2021-06-03 |
Family
ID=69730257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/102452 WO2021103581A1 (zh) | 2019-11-28 | 2020-07-16 | 具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2022549102A (zh) |
KR (1) | KR20220051191A (zh) |
CN (1) | CN110876760B (zh) |
WO (1) | WO2021103581A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110731922B (zh) * | 2019-07-30 | 2022-08-02 | 浙江养生堂天然药物研究所有限公司 | 增强的防脱生发组合物 |
CN110731925A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 美白化妆品组合物 |
CN110731974B (zh) * | 2019-07-30 | 2022-09-02 | 浙江养生堂天然药物研究所有限公司 | 具有增强的抗炎功效的皮肤外用组合物 |
CN110876760B (zh) * | 2019-11-28 | 2022-09-30 | 浙江养生堂天然药物研究所有限公司 | 具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物 |
CN111281940B (zh) * | 2020-04-14 | 2021-08-03 | 浙江沃野神生物科技有限公司 | 祛疤痕组合物及其制备方法与应用 |
CN113456733A (zh) * | 2021-07-29 | 2021-10-01 | 福建百想生物科技有限公司 | 一种具有促进伤口愈合的护理软膏及制备方法 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996024366A1 (en) * | 1995-02-10 | 1996-08-15 | Domien Jadoulle | Oral hair restorer comprising a birch sap |
US20140154374A1 (en) * | 2012-11-30 | 2014-06-05 | Feronia Holdings, Llc | Birch Sap Beverage |
CN107837224A (zh) * | 2017-12-22 | 2018-03-27 | 珍尔姿(广州)化妆品有限公司 | 一种含白桦提取物的功效性外用组合物 |
CN110731921A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 具有祛痘功效的皮肤外用组合物 |
CN110731928A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 抗衰老化妆品组合物 |
CN110731973A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 具有抗炎功效的皮肤外用组合物 |
CN110731976A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 防脱生发组合物 |
CN110731925A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 美白化妆品组合物 |
CN110731929A (zh) * | 2019-08-21 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 混合的桦树汁及其在护肤化妆品组合物中的应用 |
CN110731975A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 具有抗湿疹功效的皮肤外用组合物 |
CN110731926A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 保湿化妆品组合物 |
CN110876760A (zh) * | 2019-11-28 | 2020-03-13 | 浙江养生堂天然药物研究所有限公司 | 具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000119156A (ja) * | 1998-10-14 | 2000-04-25 | Kose Corp | 皮膚外用剤 |
JP2007320921A (ja) * | 2006-06-01 | 2007-12-13 | Nitta Gelatin Inc | 樹液配合化粧料 |
FR2967348B1 (fr) * | 2010-11-17 | 2013-05-10 | Oreal | Composition cosmetique pour le contour des yeux |
CN102784299A (zh) * | 2012-08-16 | 2012-11-21 | 武汉东保科技开发有限责任公司 | 促进伤口愈合不留瘢痕色素的外用膏及其制备方法 |
EA035486B1 (ru) * | 2015-09-17 | 2020-06-24 | Нордик Койву Ой | Способ и устройство для сбора древесного сока |
CN106490439A (zh) * | 2016-10-03 | 2017-03-15 | 嘉荫丰实绿色食品有限责任公司 | 一种桦树浓缩液的保鲜方法 |
CN107019660B (zh) * | 2017-04-27 | 2018-05-11 | 养生堂(上海)化妆品研发有限公司 | 保湿化妆品组合物 |
CN107049865B (zh) * | 2017-04-27 | 2018-03-27 | 养生堂(上海)化妆品研发有限公司 | 护肤化妆品组合物 |
-
2019
- 2019-11-28 CN CN201911189594.4A patent/CN110876760B/zh active Active
-
2020
- 2020-07-16 WO PCT/CN2020/102452 patent/WO2021103581A1/zh active Application Filing
- 2020-07-16 KR KR1020227007759A patent/KR20220051191A/ko active Search and Examination
- 2020-07-16 JP JP2022516746A patent/JP2022549102A/ja active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996024366A1 (en) * | 1995-02-10 | 1996-08-15 | Domien Jadoulle | Oral hair restorer comprising a birch sap |
US20140154374A1 (en) * | 2012-11-30 | 2014-06-05 | Feronia Holdings, Llc | Birch Sap Beverage |
CN107837224A (zh) * | 2017-12-22 | 2018-03-27 | 珍尔姿(广州)化妆品有限公司 | 一种含白桦提取物的功效性外用组合物 |
CN110731921A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 具有祛痘功效的皮肤外用组合物 |
CN110731928A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 抗衰老化妆品组合物 |
CN110731973A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 具有抗炎功效的皮肤外用组合物 |
CN110731976A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 防脱生发组合物 |
CN110731925A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 美白化妆品组合物 |
CN110731975A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 具有抗湿疹功效的皮肤外用组合物 |
CN110731926A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 保湿化妆品组合物 |
CN110731929A (zh) * | 2019-08-21 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 混合的桦树汁及其在护肤化妆品组合物中的应用 |
CN110876760A (zh) * | 2019-11-28 | 2020-03-13 | 浙江养生堂天然药物研究所有限公司 | 具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物 |
Non-Patent Citations (1)
Title |
---|
BARBER VAL, CASCIO JULIE: "Birch Tree Tapping", 1 May 2012 (2012-05-01), XP055776628, Retrieved from the Internet <URL:http://www.hackteria.org/wordpress/wp-content/uploads/2012/04/Birch-Tree-Tapping.pdf> [retrieved on 20210216] * |
Also Published As
Publication number | Publication date |
---|---|
JP2022549102A (ja) | 2022-11-24 |
CN110876760B (zh) | 2022-09-30 |
CN110876760A (zh) | 2020-03-13 |
KR20220051191A (ko) | 2022-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021103581A1 (zh) | 具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物 | |
JP7422214B2 (ja) | 抗ざ瘡有効性を有する皮膚局所用組成物 | |
CN110731921A (zh) | 具有祛痘功效的皮肤外用组合物 | |
JP6912830B2 (ja) | 医薬組成物の製造方法とその医薬組成物 | |
WO2021017910A1 (zh) | 具有增强的抗炎功效的皮肤外用组合物 | |
CN106420381A (zh) | 青蒿素类成分或其组合物在皮肤护理中的新应用 | |
CN102458431B (zh) | 用于处理伤口、皮肤疾病和脱发的滨豇豆、椰子树或榄仁树提取物中的一种或多种 | |
CN104856978B (zh) | 一种壳聚糖喷雾膜剂及其制备方法 | |
KR102026409B1 (ko) | 유근피 또는 유백피 파우더를 유효성분으로 포함하는 창상 치료 및 피부 재생용 조성물 | |
Charde et al. | Evaluation of ethanolic extract of Moringa oleifera for wound healing, anti-inflammatory and antioxidant activities on rats | |
CN109833431A (zh) | 一种抑菌凝胶及其制备方法 | |
CN109125207A (zh) | 一种抑菌祛痘的植物复方组合物及其制备方法和应用 | |
CN103071058A (zh) | 一种石斛提取物及其应用 | |
CN110200988A (zh) | 一种疤痕修复剂及其制备方法 | |
KR101679391B1 (ko) | 피뿌리풀 추출물 또는 그의 분획물을 포함하는 상처를 치료하기 위한 조성물 및 개체의 상처를 치료하는 방법 | |
JP2010222273A (ja) | 養毛剤組成物 | |
CN103191163B (zh) | 一种皮肤创面修复药物组合物 | |
GÜRLEK KISACIK et al. | Effectiveness of bitter melon extract in the treatment of ischemic wounds in rats. | |
KR100860350B1 (ko) | 생약추출물을 함유하는 모발생장촉진용 화장료 조성물 | |
Hapsari et al. | Burn healing with binahong (Anredera cordifolia (Tenore) Steenis) leaves extract as a topical and systemic treatments | |
Puspasari et al. | Effect of the water extract of the four o’clock herb (Mirabilis Jalapa L.) on the healing of open wounds in rats | |
CN112206259B (zh) | 一种治疗阴道炎的中药组合物、中药洗剂及应用 | |
CN107007650A (zh) | 鲜横根费菜汁在制备治疗皮肤瘙痒药物中的应用 | |
Gupta et al. | Preparation and Evaluation of Topical Polyherbal Emulgel Formulation for its Wound Healing Potential | |
KR100860349B1 (ko) | 생약추출물을 함유하는 모발생장촉진용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20893484 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20227007759 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022516746 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20893484 Country of ref document: EP Kind code of ref document: A1 |